18621636

Source:http://linkedlifedata.com/resource/pubmed/id/18621636

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0004083, umls-concept:C0030705, umls-concept:C0036525, umls-concept:C0205210, umls-concept:C0449438, umls-concept:C0879427, umls-concept:C1274040, umls-concept:C1522484, umls-concept:C1527249
pubmed:issue	3
pubmed:dateCreated	2008-7-14
pubmed:abstractText	Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101120693
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/panitumumab, http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1533-0028
pubmed:author	pubmed-author:AmadoRafael GRG, pubmed-author:BEAUCHAMPW SWS, pubmed-author:BerlinJordanJ, pubmed-author:FreemanDaniel JDJ, pubmed-author:JuanToddT, pubmed-author:MeropolNeal JNJ, pubmed-author:MitchellEdithE, pubmed-author:RadinskyRobertR, pubmed-author:ReinerMaureenM, pubmed-author:SarosiIldikoI
pubmed:issnType	Print
pubmed:volume	7
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	184-90
pubmed:meshHeading	pubmed-meshheading:18621636-Adult, pubmed-meshheading:18621636-Aged, pubmed-meshheading:18621636-Aged, 80 and over, pubmed-meshheading:18621636-Antibodies, Monoclonal, pubmed-meshheading:18621636-Antineoplastic Agents, pubmed-meshheading:18621636-Clinical Trials, Phase II as Topic, pubmed-meshheading:18621636-Colorectal Neoplasms, pubmed-meshheading:18621636-DNA, Viral, pubmed-meshheading:18621636-Disease Progression, pubmed-meshheading:18621636-Female, pubmed-meshheading:18621636-Humans, pubmed-meshheading:18621636-Male, pubmed-meshheading:18621636-Middle Aged, pubmed-meshheading:18621636-Mutation, pubmed-meshheading:18621636-Proto-Oncogene Proteins, pubmed-meshheading:18621636-Survival Rate, pubmed-meshheading:18621636-Treatment Outcome, pubmed-meshheading:18621636-Tumor Markers, Biological, pubmed-meshheading:18621636-ras Proteins
pubmed:year	2008
pubmed:articleTitle	Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.
pubmed:affiliation	Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA. dfreeman@amgen.com
pubmed:publicationType	Journal Article